This Article Figures Only Full Text Full Text (PDF) View Online Appendix View Cardiosource Slide Set View CVN Interview All Versions of this Article: j.jacc.2007.07.058v1 50/19/1852    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (69) Citing Articles via Google Scholar Google Scholar Articles by Storey, R. F. Articles by Cannon, C. P. Search for Related Content PubMed PubMed Citation Articles by Storey, R. F. Articles by Cannon, C. P.

CLINICAL RESEARCH: CLINICAL TRIAL

Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y₁₂ Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes

Robert F. Storey, MD^_*,1,_*, Steen Husted, MD^,1, Robert A. Harrington, MD, FACC^,1, Stanley Heptinstall, PhD^,1, Robert G. Wilcox, MD^,1, Gary Peters, MD^||,2, Mark Wickens, BSc^¶,2, Håkan Emanuelsson, MD, PhD^#,2, Paul Gurbel, MD, FACC^_**,1, Peer Grande, MD and Christopher P. Cannon, MD, FACC^,1

^_* Cardiovascular Research Unit, University of Sheffield, Sheffield, United Kingdom
Department of Medicine and Cardiology, Århus University Hospital, Århus, Denmark
Division of Cardiovascular Medicine, Duke Clinical Research Institute, Durham, North Carolina
Cardiovascular Medicine, University of Nottingham, Nottingham, United Kingdom
^|| AstraZeneca R&D, Wilmington, Delaware
^¶ AstraZeneca R&D, Charnwood, United Kingdom
^# AstraZeneca R&D, Mölndal, Sweden
^_** Sinai Center for Thrombosis Research, Baltimore, Maryland
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts.

Manuscript received May 18, 2007; revised manuscript received July 19, 2007, accepted July 24, 2007.

^_* Reprint requests and correspondence: Dr. Robert F. Storey, Cardiovascular Research Unit, School of Medicine and Biomedical Sciences, Beech Hill Road, Sheffield S10 2RX, United Kingdom. (Email: r.f.storey{at}sheffield.ac.uk).

Objectives: In a substudy of DISPERSE (Dose confIrmation Study assessing anti-Platelet Effects of AZD6140 vs. clopidogRel in non–ST-segment Elevation myocardial infarction)-2, we compared the antiplatelet effects of AZD6140 and clopidogrel and assessed the effects of AZD6140 in clopidogrel-pretreated patients.

Background: Clopidogrel, in combination with aspirin, reduces cardiovascular events in patients with acute coronary syndromes (ACS). However, patients with poor inhibition of platelet aggregation with clopidogrel may be less well protected. AZD6140 is a reversible oral P2Y₁₂ receptor antagonist that has been studied in ACS patients in comparison with clopidogrel (DISPERSE-2 study).

Methods: Patients were randomized to receive either AZD6140 90 mg twice a day, AZD6140 180 mg twice a day, or clopidogrel 75 mg once a day for up to 12 weeks in a double-blind, double-dummy design. One-half the patients allocated AZD6140 received a 270-mg loading dose. Patients randomized to receive clopidogrel were given a 300-mg loading dose unless they had already been treated with clopidogrel. Adenosine diphosphate-induced platelet aggregation was assessed by optical aggregometry on day 1 and at 4-week intervals.

Results: AZD6140 inhibited platelet aggregation in a dose-dependent fashion and both doses achieved greater levels of inhibition than clopidogrel (e.g., 4 weeks, 4-h postdose [mean (±SD)]: clopidogrel 64% [±22%], AZD6140 90 mg 79% [±22%], AZD6140 180 mg 95% [±8%]. AZD6140 also produced further suppression of platelet aggregation in patients previously treated with clopidogrel.

Conclusions: AZD6140 exhibited greater mean inhibition of platelet aggregation than a standard regimen of clopidogrel in ACS patients. In addition, AZD6140 further suppressed platelet aggregation in clopidogrel pretreated patients.

Abbreviations and Acronyms   ACS = acute coronary syndromes   ADP = adenosine diphosphate   bid = twice-daily administration   qd = once-daily administration

This article has been cited by other articles:

				P. O. Vandvik, A. M. Lincoff, J. M. Gore, D. D. Gutterman, F. A. Sonnenberg, P. Alonso-Coello, E. A. Akl, M. G. Lansberg, G. H. Guyatt, and F. A. Spencer Primary and Secondary Prevention of Cardiovascular Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest, February 1, 2012; 141(2_suppl): e637S - e668S. [Abstract] [Full Text] [PDF]

				R. F. Storey, R. C. Becker, R. A. Harrington, S. Husted, S. K. James, F. Cools, P. G. Steg, N. S. Khurmi, H. Emanuelsson, A. Cooper, et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes Eur. Heart J., December 1, 2011; 32(23): 2945 - 2953. [Abstract] [Full Text] [PDF]

				K. Butler and R. Teng Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Mild Hepatic Impairment J. Clin. Pharmacol., July 1, 2011; 51(7): 978 - 987. [Abstract] [Full Text] [PDF]

				B. M. Scirica, C. P. Cannon, H. Emanuelsson, E. L. Michelson, R. A. Harrington, S. Husted, S. James, H. Katus, P. Pais, D. Raev, et al. The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial: Results of the Continuous Electrocardiographic Assessment Substudy J. Am. Coll. Cardiol., May 10, 2011; 57(19): 1908 - 1916. [Abstract] [Full Text] [PDF]

				D. Zhou, T. B. Andersson, and S. W. Grimm In Vitro Evaluation of Potential Drug-Drug Interactions with Ticagrelor: Cytochrome P450 Reaction Phenotyping, Inhibition, Induction, and Differential Kinetics Drug Metab. Dispos., April 1, 2011; 39(4): 703 - 710. [Abstract] [Full Text] [PDF]

				K. G. Aragam and D. L. Bhatt Review: Antiplatelet Therapy in Acute Coronary Syndromes Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2011; 16(1): 24 - 42. [Abstract] [PDF]

				J. L. Ferreiro and D. J. Angiolillo Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome Circulation, February 22, 2011; 123(7): 798 - 813. [Full Text] [PDF]

				R. Hall and C. D. Mazer Review Article: Antiplatelet Drugs: A Review of Their Pharmacology and Management in the Perioperative Period Anesth. Analg., February 1, 2011; 112(2): 292 - 318. [Abstract] [Full Text] [PDF]

				S. B. Patil, L. E. Jackman, S. E. Francis, H. M. Judge, S. Nylander, and R. F. Storey Ticagrelor Effectively and Reversibly Blocks Murine Platelet P2Y12-Mediated Thrombosis and Demonstrates a Requirement for Sustained P2Y12 Inhibition to Prevent Subsequent Neointima Arterioscler Thromb Vasc Biol, December 1, 2010; 30(12): 2385 - 2391. [Abstract] [Full Text] [PDF]

				P. G. Steg, S. James, R. A. Harrington, D. Ardissino, R. C. Becker, C. P. Cannon, H. Emanuelsson, A. Finkelstein, S. Husted, H. Katus, et al. Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis Circulation, November 23, 2010; 122(21): 2131 - 2141. [Abstract] [Full Text] [PDF]

				R. F. Storey, D. J. Angiolillo, S. B. Patil, B. Desai, R. Ecob, S. Husted, H. Emanuelsson, C. P. Cannon, R. C. Becker, and L. Wallentin Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes: The PLATO (PLATelet inhibition and patient Outcomes) PLATELET Substudy J. Am. Coll. Cardiol., October 26, 2010; 56(18): 1456 - 1462. [Abstract] [Full Text] [PDF]

				J. L. Ferreiro, A. R. Cequier, and D. J. Angiolillo Review article: Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease Diabetes and Vascular Disease Research, October 1, 2010; 7(4): 274 - 288. [Abstract] [PDF]

				E. Mahla, H. Metzler, U. S. Tantry, and P. A. Gurbel Controversies in Oral Antiplatelet Therapy in Patients Undergoing Aortocoronary Bypass Surgery Ann. Thorac. Surg., September 1, 2010; 90(3): 1040 - 1051. [Abstract] [Full Text] [PDF]

				R. Teng, S. Oliver, M. A. Hayes, and K. Butler Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy Subjects Drug Metab. Dispos., September 1, 2010; 38(9): 1514 - 1521. [Abstract] [Full Text] [PDF]

				M. H. Buch, B. D. Prendergast, and R. F. Storey Antiplatelet therapy and vascular disease: an update Therapeutic Advances in Cardiovascular Disease, August 1, 2010; 4(4): 249 - 275. [Abstract] [PDF]

				S. Nathan Management of non-ST-segment elevation acute coronary syndromes: Introduction Am. J. Health Syst. Pharm., August 1, 2010; 67(15_Supplement_7): S3 - S6. [Full Text] [PDF]

				S. A. Spinler Oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention: Balancing efficacy and bleeding risk Am. J. Health Syst. Pharm., August 1, 2010; 67(15_Supplement_7): S7 - S17. [Abstract] [Full Text] [PDF]

				S. B. Damani and E. J. Topol The Case for Routine Genotyping in Dual-Antiplatelet Therapy J. Am. Coll. Cardiol., July 6, 2010; 56(2): 109 - 111. [Abstract] [Full Text] [PDF]

				F. S. Resnic and A. Desai Highlights from the 59th annual scientific sessions of the american college of cardiology, march 13 to 17, 2010, atlanta, georgia. J. Thorac. Cardiovasc. Surg., July 1, 2010; 140(1): 257 - 259. [Full Text] [PDF]

				P. A. Gurbel, K. P. Bliden, K. Butler, M. J. Antonino, C. Wei, R. Teng, L. Rasmussen, R. F. Storey, T. Nielsen, J. W. Eikelboom, et al. Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study Circulation, March 16, 2010; 121(10): 1188 - 1199. [Abstract] [Full Text] [PDF]

				S. D Anderson, N. K Shah, J. Yim, and B. J Epstein Efficacy and Safety of Ticagrelor: A Reversible P2Y12 Receptor Antagonist Ann. Pharmacother., March 1, 2010; 44(3): 524 - 537. [Abstract] [Full Text] [PDF]

				P. A. Gurbel and U. S. Tantry Combination Antithrombotic Therapies Circulation, February 2, 2010; 121(4): 569 - 583. [Full Text] [PDF]

				A. O. Abualsaud and M. J. Eisenberg Perioperative Management of Patients With Drug-Eluting Stents J. Am. Coll. Cardiol. Intv., February 1, 2010; 3(2): 131 - 142. [Abstract] [Full Text] [PDF]

				M. Cattaneo New P2Y12 Inhibitors Circulation, January 5, 2010; 121(1): 171 - 179. [Full Text] [PDF]

				P. A. Gurbel, K. P. Bliden, K. Butler, U. S. Tantry, T. Gesheff, C. Wei, R. Teng, M. J. Antonino, S. B. Patil, A. Karunakaran, et al. Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET Study Circulation, December 22, 2009; 120(25): 2577 - 2585. [Abstract] [Full Text] [PDF]

				J.-P. Collet and G. Montalescot Review: Platelet Function Testing and Implications for Clinical Practice Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2009; 14(3): 157 - 169. [Abstract] [PDF]

				L. Wallentin P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use Eur. Heart J., August 2, 2009; 30(16): 1964 - 1977. [Abstract] [Full Text] [PDF]

				M. S. SABATINE Novel antiplatelet strategies in acute coronary syndromes Cleveland Clinic Journal of Medicine, April 1, 2009; 76(Suppl_1): S8 - S15. [Abstract] [Full Text] [PDF]

				Y.-H. Jeong, S.-W. Lee, B.-R. Choi, I.-S. Kim, M.-K. Seo, C. H. Kwak, J.-Y. Hwang, and S.-W. Park Randomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity: Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) Randomized Study J. Am. Coll. Cardiol., March 31, 2009; 53(13): 1101 - 1109. [Abstract] [Full Text] [PDF]

				A. Colombo and R. T. Gerber Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Not Be Continued for More Than 1 Year and Preferably Indefinitely Circ Cardiovasc Interv, December 1, 2008; 1(3): 226 - 232. [Full Text] [PDF]

				M. Ferenc, M. Gick, R.-P. Kienzle, H.-P. Bestehorn, K.-D. Werner, T. Comberg, P. Kuebler, H. J. Buttner, and F.-J. Neumann Randomized trial on routine vs. provisional T-stenting in the treatment of de novo coronary bifurcation lesions Eur. Heart J., December 1, 2008; 29(23): 2859 - 2867. [Abstract] [Full Text] [PDF]

				G. De Luca Adjunctive antithrombotic therapy during primary percutaneous coronary intervention Eur. Heart J. Suppl., December 1, 2008; 10(suppl_J): J2 - J14. [Abstract] [Full Text] [PDF]

				R. P. Giugliano and E. Braunwald The Year in Non-ST-Segment Elevation Acute Coronary Syndrome J. Am. Coll. Cardiol., September 23, 2008; 52(13): 1095 - 1103. [Full Text] [PDF]

				M. J. Price New antiplatelet therapies in development Am. J. Health Syst. Pharm., July 1, 2008; 65(13_Supplement_5): S11 - S15. [Abstract] [Full Text] [PDF]

				R. F. Storey New developments in antiplatelet therapy Eur. Heart J. Suppl., May 1, 2008; 10(suppl_D): D30 - D37. [Abstract] [Full Text] [PDF]

				D. J. Kereiakes and P. A. Gurbel Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 111 - 121. [Abstract] [Full Text] [PDF]

				A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al. Highlights of the Year in JACC 2007 J. Am. Coll. Cardiol., January 29, 2008; 51(4): 490 - 512. [Full Text] [PDF]

				R. F. Storey Variability of response to antiplatelet therapy Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A21 - A27. [Abstract] [Full Text] [PDF]

				C. P. Cannon, S. Husted, R. A. Harrington, B. M. Scirica, H. Emanuelsson, G. Peters, R. F. Storey, and for the DISPERSE-2 Investigators Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: Primary Results of the DISPERSE-2 Trial J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1844 - 1851. [Abstract] [Full Text] [PDF]